Photo: The White House from Washington, DC | Public domain | Wikimedia Commons
Trump Executive Order Fast-Tracks FDA Psychedelic Reviews And Directs VA Trials For PTSD
President Donald Trump signed an executive order directing the FDA to fast-track psychedelic drug reviews and the VA to run PTSD trials.
The order, signed April 18, 2026, in the Oval Office, named ibogaine, psilocybin, MDMA and LSD for expedited study and urged the Veterans Affairs health system to begin PTSD trials. It directs the Food and Drug Administration to give three psychedelics national priority vouchers that FDA Commissioner Marty Makary said will cut review times from months to weeks. The order also earmarks $50 million for federal research on ibogaine and opens a pathway for use by "desperately ill" patients under Right To Try rules, according to administration statements.
Scientific evidence remains limited for ibogaine, with mostly small studies and one randomized trial and only early larger trials underway. Ibogaine is a Schedule I drug associated with at least 27 deaths linked to cardiac arrhythmias, and a 2023 review described its heart risks as "worrying." Separately, a 2025 JAMA study found a single LSD dose eased anxiety and depression for months, highlighting mixed but promising early signals across psychedelics. The FDA will begin steps to allow the first ibogaine human trials in the United States, and the VA is already participating in at least five psychedelic trials in New York, California and Oregon.
Initial mainstream coverage framed the order as an urgent, hopeful push to accelerate care for veterans and others, spotlighting Trump and podcaster Joe Rogan's role in drawing attention. Early reports from CBS, NPR and PBS highlighted the Oval Office signing, veterans' enthusiasm, and promises to "dramatically accelerate" access if trials show benefit. Later coverage, notably from Fox News and other outlets, introduced stronger caution about limited evidence, safety risks and possible politicization, shifting the tone from optimism to scrutiny. Researchers including Frederick Barrett and critics such as Kevin Sabet emphasized cardiovascular concerns and the need for careful, evidence-based trials before broader access.
Donald Trump
FDA and Drug Policy
Psychedelic Medicine
Drug Policy and Psychedelic Research
Veterans' Mental Health
This story is compiled from 7 sources using AI-assisted curation and analysis. Original reporting is attributed below. Learn about our methodology.
📌 Key Facts
- President Trump signed an executive order on April 18, 2026, in the Oval Office to hasten federal research and regulatory review of psychedelic drugs; podcaster Joe Rogan stood behind him at the signing and was publicly credited with prompting the move (reports say Rogan texted Trump about ibogaine).
- The order directs the FDA to fast-track reviews by adding three psychedelics to a National Priority Voucher pilot program — cutting review times from months to weeks — marking the first time psychedelics have been given this type of expedited treatment.
- The order explicitly targets ibogaine and also lists psilocybin, MDMA and LSD for increased research and potential approval aimed at treating PTSD, depression and addiction; ibogaine and psilocybin remain Schedule I substances under DEA rules.
- The administration is directing $50 million in federal research funding for ibogaine, will open a pathway for ‘desperately ill’ patients to access ibogaine under the FDA’s Right To Try authorities, and the FDA will begin the process to allow first-ever ibogaine human trials in the United States.
- The executive order requires the Department of Veterans Affairs to begin psychedelics research and clinical trials — including at least five VA-participating trials in New York, California and Oregon — with an emphasis on veterans who have not responded to SSRIs and talk therapy.
- Scientific evidence for ibogaine is limited (small studies and one randomized trial), with larger trials only in early stages; significant safety concerns exist — ibogaine has been linked to cardiotoxicity and at least 27 deaths from cardiac arrhythmias, and past NIH funding was halted over cardiovascular risk concerns.
- Reactions are mixed: administration officials and veteran advocates hailed the move as a potentially transformative option for treatment-resistant conditions, while drug-policy experts and some researchers warned about limited evidence, politicization, and the need for more rigorous study and careful dosing.
- FDA Commissioner Makary (reported by outlets) announced the priority-voucher fast-tracking plan and administration officials framed the effort as a way to “dramatically accelerate” access, saying the drugs could have a “tremendous impact” if proven safe and effective.
📰 Source Timeline (7)
Follow how coverage of this story developed over time
April 19, 2026
1:00 PM
Trump-backed plan could fast-track psychedelic therapies — here’s what to know
New information:
- Article reiterates that Trump signed an April 18, 2026 executive order to fast-track research, funding and potential FDA approval of ibogaine, psilocybin, LSD and MDMA for PTSD, depression and addiction.
- It states that the executive order will require the Veterans Affairs health system to begin psychedelics research and clinical trials and make those therapies available to veterans who have not responded to SSRIs and talk therapy.
- Provides on-the-record reaction from Jay Kopelman, former Marine Corps lieutenant colonel and CEO of Mission to Live Foundation, calling the order a pathway to expedited approval for treatment-resistant PTSD, TBI and depression.
- Includes comments from Fox medical contributor Dr. Marc Siegel saying psychedelics hold 'big potential' for severe depression and PTSD by modulating dopamine and serotonin but stressing the need for more research and careful dosing.
- Features praise from veteran advocate Juliana Mercer of Healing Breakthrough, who frames the move as a meaningful step for veterans who have tried years of therapy and medications without relief.
- Introduces critical perspective from drug-policy figure Kevin Sabet, who warns about limited evidence and politicization around ibogaine (partially visible in the excerpt but clearly present as a counterpoint).
April 18, 2026
6:56 PM
Trump signs order fast tracking review of psychedelics for mental health disorders
New information:
- NPR pins the signing to Saturday, April 18, 2026, and describes it as taking place in the Oval Office with specific participants present.
- The story specifies that Trump directed $50 million in federal funds to make certain psychedelics more accessible for mental health treatment.
- It clarifies that the executive order tasks FDA with fast tracking reviews of psilocybin and ibogaine and that ibogaine and psilocybin remain Schedule I drugs under DEA rules.
- FDA Commissioner Mary Makary is quoted as saying national priority vouchers for three psychedelics will allow approvals within weeks, and that this is the first time FDA has fast tracked any psychedelics.
- The article adds context on a 2025 JAMA study finding a single LSD dose eased anxiety and depression for months and restates national prevalence figures for serious mental illness, depression, and generalized anxiety disorder.
- It confirms that the Department of Veterans Affairs is participating in at least five psychedelic trials in New York, California, and Oregon.
5:00 PM
Trump signs executive order on psychedelic drugs — with Joe Rogan by his side
New information:
- Trump signed the executive order in the Oval Office with Joe Rogan standing directly behind him and publicly credited Rogan's call as a catalyst, saying Rogan told him 'We have to do something about this.'
- The order explicitly lists ibogaine, psilocybin, MDMA and LSD as psychedelics the FDA is directed to support in clinical trials and speed toward approval if found safe and effective.
- Rogan said he learned about ibogaine's potential from a podcast interview with Americans for Ibogaine CEO W. Bryan Hubbard and former Energy Secretary Rick Perry, both present at the signing.
- Trump joked about wanting ibogaine himself and cited a study he said showed major reductions in depression and anxiety symptoms within a month for people who took the drug.
- The article underscores that Rogan has recently criticized Trump on immigration, the Epstein files and the Iran war, yet appeared friendly with him at the signing, with Trump calling him a 'fantastic person.'
4:30 PM
Watch: Trump signs executive order easing U.S. restrictions on psychedelic research
New information:
- CBS clip confirms Trump signed an executive order specifically described as easing U.S. restrictions on psychedelic research.
- CBS explicitly frames ibogaine as a psychedelic used in some countries to treat post-traumatic stress disorder.
4:27 PM
Trump signs order to hasten review of psychedelics
New information:
- Confirms the order was signed Saturday, April 18, 2026, in the Oval Office.
- Details that FDA will issue new national priority vouchers for three psychedelics, cutting review times from months to weeks, marking the first time psychedelics receive this fast-tracking.
- States FDA is taking steps to clear the way for the first-ever ibogaine human trials in the United States.
- Quotes Trump promising to "dramatically accelerate" access and saying if the drugs are as good as advocates claim they will have a "tremendous impact."
- Reports that Joe Rogan personally texted Trump about ibogaine and that Trump replied, "Sounds great. Do you want FDA approval? Let's do it."
- Includes on-the-record enthusiasm from veteran Marcus Luttrell and explicit acknowledgment from researchers like Frederick Barrett about ibogaine's cardiotoxicity and past NIH funding being halted over cardiovascular risks.
1:46 PM
Trump signs order to research psychedelic used abroad to treat PTSD
New information:
- Executive order explicitly eases federal restrictions on ibogaine and is framed around post-traumatic stress disorder treatment, especially for veterans.
- Trump announces a $50 million federal research investment specifically for ibogaine.
- The administration will open a pathway for ibogaine use by 'desperately ill' patients under FDA's Right To Try rule.
- FDA Commissioner Marty Makary says three psychedelics will be added to the National Priority Voucher pilot program to cut review times.
- FDA will begin the process to allow human trials of ibogaine in the United States.
- Scientific evidence for ibogaine remains limited to small studies and one randomized trial, with only early larger trials underway.
- Ibogaine is a Schedule I drug associated with at least 27 deaths from cardiac arrhythmias, and a 2023 review called heart risks 'worrying.'